Sells Papzimeos, an immunotherapy for adults with recurrent respiratory papillomatosis, and develops therapies for cancer and other diseases; also sells miniature swine research models and services to healthcare researchers.
10-K for FY2025, filed Mar 25, 2026We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives…View ↗
In August 2025, the FDA granted full approval to our product, Papzimeos (zopapogene imadenovec-drba, PRGN-2012), for the treatment of…View ↗
Precigen Exemplar provides porcine research models and services that aid scientists in the understanding of human disease mechanisms and…View ↗
Specialty distributors buy Papzimeos for medical centers, hospitals and specialty pharmacies, with payment due after sale. Exemplar sells miniature swine models and related research services, with product sales at a point in time and service revenue as the work is provided.
10-K for FY2025, filed Mar 25, 2026In 2025, the Company received FDA approval for Papzimeos and initiated commercial sales during the fourth quarter of 2025. Product revenue…View ↗
The Company generates product and service revenues through Exemplar, which consists of the development and sale of genetically engineered…View ↗
Exemplar revenues primarily consist of over‑time service revenue and point‑in‑time product sales, whereas Papzimeos is recognized…View ↗
10-K for FY2025, filed Mar 25, 2026
FY2025 revenue by product or service ↗$9.7M
10-K for FY2025, filed Mar 25, 2026
$9.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenues, net
Sold outright
10-K for FY2025, filed Mar 25, 2026 |
41% |
Product revenues, net, FY2025
$4M Sources
|
Sold outright |
|
Service revenues
Recurring
10-K for FY2025, filed Mar 25, 2026 |
40% |
Service revenues, FY2025
$3.9M Sources
|
Recurring |
Medical centers, hospitals and specialty pharmacies obtain Papzimeos through specialty distributors; industry and academic researchers use Exemplar's models and services.
10-K for FY2025, filed Mar 25, 2026
No. It lost $250.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
$35.8MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
Shrinking. Revenue fell 32% in 4 years, from $14.3M in FY2021 to $9.7M in FY2025, about 9% a year.
Commercial product sales
The older report described a discovery- and clinical-stage drug developer; the latest describes a commercial-stage biopharma company with an approved Papzimeos product for adults with recurrent respiratory papillomatosis, alongside a development pipeline.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 25, 2026We are a dedicated discovery and clinical-stage biopharmaceutical company advancing the next generation of gene and cell therapies with the…View ↗
Competes with INOVIO Pharmaceuticals, BioNTech, PDS Biotechnology, NeoTrail Therapeutics, Nykode Therapeutics, ViciniVax, Bavarian Nordic, Kite, Iovance, Bristol-Myers Squibb, Merck, Regeneron Pharmaceuticals, Anixa Biosciences, US WorldMeds, Essen Biotech, Senti Bio, Allogene Therapeutics, Novartis, Gilead, and Janssen
10-K for FY2025, filed Mar 25, 2026While we believe that our FDA-approved product Papzimeos for the treatment of RRP, is based on a novel design of antigen targeting HPV6 and…View ↗
Loading...